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Abstract
Accumulating evidence suggests that alterations in immune function may be important in the etiology of papillary thyroid
cancer (PTC). To identify genetic markers in immune-related pathways, we evaluated 3,985 tag single nucleotide
polymorphisms (SNPs) in 230 candidate gene regions (adhesion-extravasation-migration, arachidonic acid metabolism/
eicosanoid signaling, complement and coagulation cascade, cytokine signaling, innate pathogen detection and
antimicrobials, leukocyte signaling, TNF/NF-kB pathway or other) in a case-control study of 344 PTC cases and 452
controls. We used logistic regression models to estimate odds ratios (OR) and calculate one degree of freedom P values of
linear trend (PSNP-trend) for the association between genotype (common homozygous, heterozygous, variant homozygous)
and risk of PTC. To correct for multiple comparisons, we applied the false discovery rate method (FDR). Gene region- and
pathway-level associations (PRegion and PPathway) were assessed by combining individual PSNP-trend values using the adaptive
rank truncated product method. Two SNPs (rs6115, rs6112) in the SERPINA5 gene were significantly associated with risk of
PTC (PSNP-FDR/PSNP-trend = 0.02/6610
26 and PSNP-FDR/PSNP-trend = 0.04/2610
25, respectively). These associations were indepen-
dent of a history of autoimmune thyroiditis (OR = 6.4; 95% confidence interval: 3.0–13.4). At the gene region level, SERPINA5
was suggestively associated with risk of PTC (PRegion-FDR/PRegion =0.07/0.0003). Overall, the complement and coagulation
cascade pathway was the most significant pathway (PPathway= 0.02) associated with PTC risk largely due to the strong effect
of SERPINA5. Our results require replication but suggest that the SERPINA5 gene, which codes for the protein C inhibitor
involved in many biological processes including inflammation, may be a new susceptibility locus for PTC.
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Introduction
Thyroid carcinoma is the most common endocrine malignancy
and its incidence has increased worldwide during the last 40 years
[1–3]. Although improved diagnosis and reporting have likely
contributed to this trend, additional reasons remain unclear [3].
Thyroid cancer is consistently more common in females, with a
female-to-male ratio in incidence rates of about 3 to 1 [4]. One of
the best established etiologic factors for thyroid carcinoma and its
most common histological type, papillary thyroid cancer (PTC), is
exposure to ionizing radiation during childhood [5,6]. Family
history studies suggest that thyroid cancer may have a greater
familial component than other cancers with relative risk (RR)
estimates of 3–4 or higher for a family history in first-degree
relatives [7,8]. Recent genome-wide association studies (GWAS)
[9,10] and a candidate gene study [11] have clearly implicated the
gene FOXE1, formerly known as TTF2 (thyroid transcription
factor 2), as a susceptibility locus for PTC both in persons exposed
[11] and unexposed to ionizing radiation [9,11]; however, most
genetic determinants of risk remain to be discovered.
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Apart from childhood exposure to radiation and genetic
predisposition, accumulating epidemiological, histological, and
molecular evidence suggests that alterations in immune function
might be related to risk of PTC [12,13]. Chronic inflammation
increasingly has been associated with many cancer types including
PTC [12–14]. While the exact mechanism for these associations is
unclear, it has been hypothesized that persistent inflammation
leads to increased cellular turnover and provides selection pressure
resulting in the emergence of cells that are at high risk for
malignant transformation [14]. A history of autoimmune disease,
in which inappropriate immune activation results in tissue
destruction and inflammation, has also been associated with
increased risk of PTC [15]. The most consistent associations for
PTC are reported with a history of chronic autoimmune
thyroiditis or Hashimoto thyroiditis (HT) [16,17], both more
common in females [4,18]. At a histological level, HT and PTC
share lymphoid infiltration, expression of galectin 3, CITED1,
cytokeratin 19, and fibronectin 1 through which the association
might be mediated [12,16]. At the molecular level, activation of
proinflammatory MAPK-signaling pathway through RET/PTC
rearrangement might contribute to development of HT-associated
PTC [12,17]. Recently common germline polymorphisms in
immune-related genes have been associated with risk of many
autoimmune diseases, including HT [19,20], but such data in
relation to PTC are sparse.
Given emerging relationships between immune dysfunction and
PTC, we sought to identify genetic susceptibility markers for PTC
in a case-control study of 344 PTC cases and 452 controls by
evaluating 3,985 tag single nucleotide polymorphisms (SNPs) in
230 candidate gene regions involved in various immune pathways
(adhesion-extravasation-migration, arachidonic acid metabolism/
eicosanoid signaling, complement and coagulation cascade,
cytokine signaling, innate pathogen detection and antimicrobials,
leukocyte signaling, TNF/NF-kB signaling and other). This effort
extends previous candidate gene based studies of PTC by
increasing the number and coverage of promising genes implicated
in the development of inflammation, autoimmunity, and carcino-
genesis.
Materials and Methods
Study Population
Cases included thyroid cancers (n = 202) diagnosed within the
U.S. Radiologic Technologists (USRT) cohort as described
previously [21] and cancers (n = 142) diagnosed and treated at
the University of Texas M. D. Anderson Cancer Center
(UTMDACC) [22]. All cases were histologically confirmed.
Controls (n = 452) were selected from the USRT study [23] and
frequency-matched to the USRT cases by sex and year of birth (+/
22 years). These controls were also used for the combined case
series (USRT and UTMDACC). Both studies were reviewed and
approved by the Special Studies Institutional Review Board of the
National Cancer Institute and Institution Review Board of the
University of Texas M. D. Anderson Cancer Center, respectively.
All subjects provided written informed consent.
To minimize the potential for population stratification and
phenotypic heterogeneity of thyroid cancer cases, we excluded
individuals with non-European ancestry (n = 97) and cases with
follicular thyroid cancer (n = 17) leaving 344 papillary thyroid
cancer cases (n = 202 USRT and n=142 UTMDACC) and 452
controls of European ancestry with validated genotyping results.
Allele frequencies for papillary thyroid cancer cases of European
ancestry were largely similar between the USRT and the
UTMDACC study sites and between males and females, so
these groups were combined for genetic analyses.
Variable Collection and Data Harmonization
Data concerning demographics, health history, family history of
cancer, and other risk factors were collected by self-administered
mailed questionnaires or telephone interview in the USRT study
or a self-administered questionnaire at the time of blood collection
in the UTMDACC study. Race, histological type of thyroid
cancer, and history of autoimmune thyroiditis were defined
similarly in both studies. Other variables were harmonized across
the two studies (cigarette smoking, alcohol consumption, prior
exposure to therapeutic radiation, and family history of any cancer
or specifically of thyroid cancer). Because controls were matched
to cases on year of birth (+/22 years), and to enable time-
appropriate partitioning of exposures (such as cigarette smoking),
we assigned a referent age to controls to correspond to the time of
a case’s diagnosis. Specifically, a control for a particular case was
randomly selected from case-defined strata of sex and year of
birth. If no control could be found then matching on sex and year
of birth was relaxed (in that order). The algorithm was repeated
until referent age was assigned to every control. Time dependent
exposures in controls were accounted for up to the referent age
and ignored thereafter.
Laboratory Methods
DNA extraction. In the USRT study, venipuncture whole
blood samples were shipped with a temperature stabilizing pack
overnight to the processing laboratory in Frederick, MD. At
UTMDACC, venipuncture whole blood samples were collected
and processed in the clinic. Both studies extracted DNA from
peripheral blood leucocytes using Qiagen Mini Kits (Qiagen Inc.,
Valencia, CA) according to the manufacturer’s instructions.
Genotyping. Genotyping of 27,904 SNPs, including tag
SNPs in 1,316 candidate genes and their surrounding regions
(within 20 kb 59 of the start of transcription at the first exon and
10 kb 39 of the last exon) and intergenic SNPs included on the
platform because of associations with several cancers, was
performed at the NCI Core Genotyping Facility (Advanced
Technology Center, Gaithersburg, MD; http://cgf.nci.nih.gov/)
using the custom-designed iSelect Infinium assay (Illumina, www.
illumna.com). Tag SNPs were selected for target gene regions from
the common SNPs (minor allele frequency, MAF.5%) genotyped
by the HapMap Project (Data Release 20/Phase II, NCBI Build
36.1, assembly dbSNPb126) in the Caucasian population (CEU)
using TagZilla software (http://tagzilla.nci.nih.gov/) based on the
pairwise binning method of Carlson et al. [24] with a binning
threshold of r2.0.8.
Quality control. Out of 27,904 SNPs included in the
genotyping platform, 722 failed genotyping (no amplification or
clustering) and 208 had monoallelic calls and were excluded from
the analysis. SNPs with ,95% concordance (n = 656) or ,90%
completion (n= 740) among randomly inserted quality control
replicates, and 740 SNPs that failed the Hardy-Weinberg
Equilibrium test in controls (P value ,0.00001) were also
excluded. Of the 947 study participants with DNA specimens
(n = 232 USRT cases, n = 223 UTMDACC cases, n = 492 USRT
controls), we excluded subjects if their samples failed genotyping
(n= 18), were not assayed (n = 4), or had less than 90% completion
rate (n = 15).
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Final Set of Tag SNPs, Sub-pathways, and Analytic
Population
Following quality control related exclusions, we also excluded in
the analysis 1,607 intergenic SNPs that had been previously
implicated in etiology of non-thyroid cancers, and 5,706 tag SNPs
with the MAF ,10% or the lowest achievable significance level
computed from the marginal totals .1230 [25]. After all
exclusions, there were 17,525 tag SNPs in 1,129 gene regions
available for analysis. Of these, 3,985 SNPs were in 230 gene
regions involved in immune-related pathways that are the subject
of the current analysis. The candidate gene regions were further
subdivided into eight a priori defined pathways (adhesion-extrav-
asation-migration, arachidonic acid metabolism/eicosanoid sig-
naling, complement and coagulation cascade, cytokine signaling,
innate pathogen detection and antimicrobials, leukocyte signaling,
TNF/NF-kB signaling, and other) largely based on classifications
from Loza et. [26]. When assigning gene regions with a broad
range of known functions, we allowed for allocation to multiple
pathways. A complete list of the 230 gene regions and their
allocation to the respective pathways is available in Table S1.
Statistical Analysis
We organized the analytic approach by first examining the
relationship of individual SNPs with PTC risk, followed by
examining relationships at the gene region level, pathway level,
and overall to also detect small SNP effects that could only be
detected in the aggregate.
SNP-based associations. Logistic regression models were
used to estimate odds ratios (ORs) and to calculate 95%
confidence intervals (CIs) of the association of PTC risk with
each SNP genotype, coded as 0, 1, 2, with 0 through 2 denoting
the number of minor alleles. We calculated the linear PSNP-trend for
SNP genotype in crude models and models adjusted for sex,
attained age in four categories (,35, 35–44, 45–54, 55+ years),
and year of birth (,1940, 1940–1949, 1950+) as an ordinal
variable. The ORs from models with and without adjustments
were very similar, so we present the results from the adjusted
models. For the top SNPs (PSNP-trend ,0.001), we repeated analyses
of main effects while also (1) adjusting for history of autoimmune
thyroiditis, (2) limiting to individuals without autoimmune
thyroiditis, and (3) limiting to females. For the top SNPs we also
conducted interaction analyses with attained age and history of
autoimmune thyroiditis. These analyses were based on one degree
of freedom likelihood ratio tests comparing the fit of two models:
(1) including main effect of genotype (0, 1, 2) and continuous age
or history of autoimmune thyroiditis (0, 1), and (2) including also
the multiplicative interaction term between the genotype and age
or autoimmune thyroiditis. To correct for multiple comparisons,
we used the false discovery rate (FDR) control method [27].
Gene region- and pathway-based analyses. We combined
SNP specific P values of linear trend within the same gene region
(PRegion) using an adaptive rank truncated product (ARTP) method
[28]. This method accounts for the linkage disequilibrium (LD)
structure within the gene region and accounts for the number of
SNPs included in the P value calculation. For the subset of genes
with PRegion ,0.01, we evaluated pairwise indices of LD (D9 and r
2)
in controls using the Haploview package [29]. Gene region-level P
values were further combined into the P values for pathways
(PPathway) and an overall P value for the entire group of immune
genes (POverall) using the ARTP method. Pathway-based analyses
were repeated including and excluding gene regions with multiple
allocations.
Statistical analyses were conducted in SAS version 9.1 (SAS
Institute, Cary, NC) and in R, unless otherwise noted.
Results
The characteristics of 344 PTC cases and 452 controls are
summarized in Table 1. There was a lower proportion of females
among cases compared to controls (79.7% vs. 93.6%) owing to the
fact that study controls were originally selected from the USRT
cohort to match the USRT cases (90.6% female), but subsequently
were used for the UTMDACC cases containing a lower
proportion of females (64.1%). The distribution of referent age
in cases and controls was comparable. After controlling for sex and
age, cases were less likely to smoke (P,0.001) or to have several
family members with a history of cancer (P= 0.009). Cases were
also less likely than controls to drink alcohol, although this
difference was not statistically significant (P=0.073), but more
likely to have at least one family member with a history of thyroid
cancer (P= 0.006), a higher body mass index (P,0.001), and a
personal history of autoimmune thyroiditis (P,0.001). The
adjusted OR associated with a history of autoimmune thyroiditis
was 6.4 (95% CI: 3.0–13.4).
SNP-based Associations
While the observed distribution of P values of linear trend for all
3,985 SNPs was not statistically different from the expected
uniform (null) distribution, there was some suggestion of departure
from the null in the area of lowest P values (Figure 1). Seven SNPs
in four gene regions were associated with risk of PTC at PSNP-trend
,0.001 (Table 2; a complete list of all PSNP-trend values is available
in Table S2). Of these, four SNPs (rs6115, rs6112, rs6108,
rs10139508) were in the SERPINA5 gene and the remaining SNPs
were in the MASP1 (rs850316), HEMGN (rs10984462), and
TICAM1 (rs2292151) genes, respectively. Two SNPs (rs6115,
rs6112) remained significant after FDR correction (PSNP-FDR=0.02
and PSNP-FDR=0.04, respectively); both were in SERPINA5. The
LD structure for the SERPINA5 gene is presented in Figure 2.
There is evidence that the two most significant SNPs (rs6115 and
rs6112) are in LD with one another (D9=0.95 and r2 = 0.47). The
associations with the top SNPs were not meaningfully changed
when analyses were adjusted for history of autoimmune thyroiditis
or restricted to individuals without history of autoimmune
thyroiditis or conducted only among females (data not shown).
Also, there was no evidence that these associations significantly
varied by attained age or history of autoimmune thyroiditis (data
not shown).
Gene Region-based Associations
Largely consistent with individual SNP analyses, four gene
regions (SERPINA5, HEMGN, TICAM1, and FCGR2A) were
associated with PTC risk at PRegion ,0.01 (Table 3). After multiple
comparisons adjustment, only SERPINA5 remained suggestively
associated with PTC risk at PRegion-FDR=0.069. All gene region-
based results are available in Table S3.
Pathway-based Associations
Two immunity pathways, complement and coagulation cascade
including the SERPINA5 gene and TNF/NF-kB signaling pathway
including the HEMGN gene, were significantly associated with risk
of PTC (PPathway = 0.02 including and PPathway = 0.02 excluding
overlap; and PPathway = 0.05 including and PPathway = 0.04 excluding
overlap, respectively) (Table 4). The immunity pathway as a whole
was not statistically significantly associated with PTC risk.
Polymorphisms in Immunity Genes and Thyroid Cancer
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Discussion
We evaluated the associations of 3,985 tag SNPs in 230
candidate genes from several immune pathways in relation to risk
of PTC. The gene collection overall was not significantly
associated with risk of PTC. In pathway-based analyses, the
complement and coagulation cascade and TNF/NF-kB signaling
pathway were significantly associated with risk of PTC. These
findings were largely attributed to the effects of SERPINA5 and
Table 1. Characteristics of the study population by case and control status, U. S. Radiologic Technologists Study and University of
Texas M. D. Anderson Cancer Center Study.
Cases (N=344) Controls (N=452)
Characteristic n (%) n (%) P a
Study
Radiologic Technologists 202 (58.7) 452 (100.0)
M. D. Anderson Cancer Center 142 (41.3) 0
Gender ,0.001
Female 274 (79.7) 423 (93.6)
Male 70 (20.3) 29 (6.4)
Attained/referent age, year 0.360
19–25 26 (7.6) 30 (6.6)
26–35 73 (21.2) 103 (22.8)
36–45 113 (32.8) 159 (35.2)
46–55 77 (22.4) 105 (23.2)
56–65 43 (12.5) 49 (10.8)
66–79 12 (3.5) 6 (1.3)
Smoking statusb ,0.001c
Never 208 (60.5) 234 (51.8)
Former 87 (25.3) 101 (22.4)
Current 48 (14.0) 113 (25.0)
Unknown 1 (0.3) 4 (0.9)
Alcohol consumptionb 0.073c
Never 179 (52.0) 213 (47.1)
Ever 158 (45.9) 221 (48.9)
Unknown 7 (2.0) 18 (4.0)
Number of relatives with cancerb 0.009c
None 170 (49.4) 171 (37.8)
One 107 (31.1) 180 (39.8)
Two 39 (11.3) 64 (14.2)
Three or more 18 (5.2) 33 (7.3)
Adopted 0 4 (0.9)
Unknown 10 (2.9) 0
Number of relatives with thyroid cancerb 0.006c
None 319 (92.7) 442 (97.8)
At least one 15 (4.4) 6 (1.3)
Adopted 0 4 (0.9)
Unknown 10 (2.9) 0
Mean (sd) Mean (sd)
BMI, kg/m2b 26.1 (6.0) 24.4 (4.7) ,0.001c
History of autoimmune thyroiditisb
No 277 (80.5) 432 (95.6) ,0.001c
Yes 48 (14.0) 9 (2.0)
Unknown 19 (5.5) 11 (2.4)
aTest of independence.
bAs of referent age. See text for description of referent age assignment.
cAdjusted for sex and attained age.
doi:10.1371/journal.pone.0057243.t001
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HEMGN genes, respectively. At the SNP level, the strongest
associations were found for two SNPs in the SERPINA5 gene
(rs6115 and rs6112), both of which persisted after FDR correction
and were independent of history of autoimmune thyroiditis. While
our findings require replication, they strongly suggest that the
SERPINA5 gene region might be a novel susceptibility locus for
PTC.
The main findings in our study are internally consistent in that
at the SNP, gene region, and pathway level they are attributed to
the SERPINA5 gene. This gene is located on human chromosome
14 at position 14q32.1 and codes the protein C inhibitor (PCI), a
member of the plasma serine protease inhibitor family [30]. While
originally it was discovered as an inhibitor of activated protein C,
today PCI is known to play a role in many biological processes
beyond hemostasis and thrombosis including inflammation, innate
immunity, carcinogenesis, and fertilization [30–33]. Recent
proteomic analysis of human multiple sclerosis lesions by sensitive
mass spectrometry implicated PCI in the development of chronic
active plaques and suggested an unexpected intersection between
coagulation and inflammation [34]. The expression of SERPINA5
was found to be significantly reduced in advanced-stage serous
ovarian borderline tumors and serous carcinomas when compared
with the early-stage counterparts, and such a reduction was linked
to more aggressive features of the ovarian borderline tumors [35].
We were unable to find any reports of changes in SERPINA5
expression in thyroid cancer, although several studies reported
over-expression in SERPINA1 (belonging to the same gene cluster
on human chromosome 14q32.1) in sporadic and radiation-related
thyroid cancers [36,37]. The relationship of over-expression in
SERPINA1 to SERPINA5 SNPs is unclear and needs to be
interpreted cautiously. To our knowledge, there have been no
reports of germline polymorphisms in SERPINA5 in relation to risk
of thyroid cancer or any other cancer, but there have been several
reports of associations with the rate of fertilization failure [38] or
risk of Wegener’s granulomatosis [39], an autoimmune vasculitis
syndrome. It is intriguing that one of the two linked SNPs in
SERPINA5 gene (rs6115), which withstood correction for multiple
comparisons, results in a serine to asparagine amino acid change
at position 64. However, whether the observed positive association
between rs6115 polymorphism and risk of PTC is due to changes
in PCI properties related to amino acid substitution or to potential
LD with another unidentified variant remains unknown and
requires further evaluation.
The second strongest association found in our study concerned
SNPs in the HEMGN gene, although these did not withstand
correction for multiple comparisons at the individual SNP and
gene level. Interestingly, the HEMGN gene is located on
chromosome 9q22.33 within a LD region including the FOXE1
gene necessary for maintenance of the differentiated state of the
thyroid [40]. Several recent GWAS and a parallel candidate gene
study reported consistent associations between variants in the
FOXE1 region (rs965513, rs1867277, rs7850258) and risk of
papillary thyroid cancer and/or primary hypothyroidism [9–
11,41,42]. Unfortunately, the FOXE1 gene was not included in our
genotyping platform, but due to extensive linkage in the area,
signal associated with HEMGN is unlikely to be independent and is
in accord with previously reported associations for variants in
FOXE1.
In interpreting the results of our study, several strengths and
limitations need to be considered. Because survival rates for
Figure 1. Observed and expected distributions for the P values of linear trend for 3,985 tag-SNPs in 230 gene regions related to
immune function in a case-control study of PTC risk.
doi:10.1371/journal.pone.0057243.g001
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Figure 2. Linkage disequlibrium (LD) representation of the SERPINA5 gene. The figure represents LD based on the genotyping data from the
study controls with European ancestry. LD is measured by D9 parameters (top panel) and the r2 correlation coefficient (bottom panel). D9 and r2
values of one are interpreted as complete LD.
doi:10.1371/journal.pone.0057243.g002
Polymorphisms in Immunity Genes and Thyroid Cancer
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PTC are exceptionally high, any associations that might be due
to survival bias are unlikely. Our study had high participation
rates, minimizing potential for selection bias. To minimize
concerns about population stratification, all analyses were
limited to individuals of European ancestry. Moreover, cases
from the two studies were similar with regard to age at
diagnosis, smoking status, tumor size, and frequency of many
alleles. Other strengths of our study include a thorough selection
of genes related to a variety of immunity pathways. The
proportion of females in the UTMDACC cases was lower than
in the USRT cases and respective controls; to assure that the
observed associations are not confounded, analyses were
adjusted for sex. Results based on adjusted analysis as well as
on analysis restricted to females were not meaningfully different.
Similarly, the observed associations appeared to be independent
of history of autoimmune thyroiditis. Relative to GWAS, the
coverage of selected gene regions was higher, although we could
have missed important associations with SNPs in gene regions
not included within the genotyping platform such as in FOXE1.
While among the larger studies in the field with respect to the
number of thyroid cancer cases and controls, our study had
limited power (,80%) to detect modest-to-weak associations
(OR ,1.7) especially for less common genetic variants (MAF
#10%). Another limitation is the use of tag SNPs that are
themselves unlikely to be the disease-related SNPs, but are
assumed to be in LD with the causal variant. To address these
limitations, we excluded SNPs with MAF ,10% and relied on
robust gene/pathway ARTP methods combining SNP-specific P
values of linear trend to confirm associations with risk of PTC.
Although we targeted genes with strong prior evidence and
adjusted for multiple comparisons using the FDR method, we
cannot exclude the possibility of false positives.
In summary, we identified a promising susceptibility locus for
PTC in the SERPINA5 gene belonging to the complement and
coagulation cascade pathway and confirmed previously reported
associations with polymorphisms in the FOXE1 - HEMGN region.
Subsequent replication and fine mapping studies with adequate
Table 2. Odds ratio and 95% confidence interval (CI), adjusted for sex, attained age, and year of birth, for the tag SNPs associated
with papillary thyroid cancer risk at PSNP-trend ,0.001.
Cases Controls
Gene Region SNP Genotype n (%) n (%) Odds Ratio 95% CI PSNP-trend
a/PSNP-FDR
b
SERPINA5 rs6115 AA 119 (35.2) 228 (51.5) 1.00 Referent
AG 148 (43.8) 161 (36.3) 1.68 1.20–2.34
GG 71 (21.0) 54 (12.2) 2.62 1.68–4.08 6.08*1026/0.02
SERPINA5 rs6112 CC 120 (34.9) 227 (50.2) 1.00 Referent
CT 182 (52.9) 196 (43.4) 1.72 1.25–2.36
TT 42 (12.2) 29 (6.4) 2.72 1.56–4.75 2.23*1025/0.04
SERPINA5 rs6108 TT 107 (31.3) 187 (41.6) 1.00 Referent
AT 173 (50.6) 218 (48.4) 1.34 0.96–1.86
AA 62 (18.1) 45 (10.0) 2.54 1.56–4.12 0.00028/0.37
SERPINA5 rs10139508 AA 118 (34.4) 208 (46.0) 1.00 Referent
AG 183 (53.4) 203 (44.9) 1.74 1.26–2.39
GG 42 (12.2) 41 (9.1) 1.90 1.12–3.20 0.00075/0.50
MASP1 rs850316 GG 79 (23.0) 157 (34.7) 1.00 Referent
AG 180 (52.3) 215 (47.6) 1.67 1.17–2.38
AA 85 (24.7) 80 (17.7) 2.04 1.32–3.15 0.00082/0.50
HEMGN rs10984462 TT 216 (63.0) 246 (54.4) 1.00 Referent
GT 114 (33.2) 166 (36.7) 0.72 0.52–0.99
GG 13 (3.8) 40 (8.8) 0.35 0.18–0.68 0.00087/0.50
TICAM1 rs2292151 GG 182 (52.9) 283 (63.0) 1.00 Referent
AG 133 (38.7) 145 (32.3) 1.50 1.09–2.07
AA 29 (8.4) 21 (4.7) 2.34 1.25–4.38 0.00088/0.50
aSNP-based linear PSNP-trend is calculated based on the three-level genotype (0, 1, and 2) in logistic regression models adjusted for sex, attained age, and year of birth.
bFalse discovery rate (FDR) corrected linear PSNP-trend.
doi:10.1371/journal.pone.0057243.t002
Table 3. Significance levels (P values) for an association with
papillary thyroid cancer for the selected gene regions with
uncorrected PRegion ,0.01.
Gene
Region
Chromosome
Band
Number of
SNPs PRegion
a/PRegion-FDR
b
SERPINA5 14q32.1 26 0.0003/0.069
HEMGN 9q22.33 5 0.0016/0.183
TICAM1 19p13.3 15 0.0066/0.426
FCGR2A 1q23 8 0.0074/0.426
aGene region-based P values (PRegion) calculated using the adaptive rank
truncated product method.
bFalse discovery rate (FDR) corrected PRegion.
doi:10.1371/journal.pone.0057243.t003
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power are essential to establish causal variants in the SERPINA5
region.
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